View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNeuropathix 配当と自社株買い配当金 基準チェック /06Neuropathix配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Aug 13Neuropathix, Inc. announced delayed 10-Q filingOn 08/12/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Neuropathix, Inc. announced delayed 10-Q filingOn 05/16/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Neuropathix, Inc. announced delayed annual 10-K filingOn 03/31/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 13Neuropathix, Inc. Appoints Daniel Richman to Board of AdvisorsNeuropathix, Inc. announced that it has appointed pain management expert Dr. Daniel Richman to the Company’s Board of Advisors. Dr. Richman is a world-renowned, board-certified attending anesthesiologist and pain management physician. Since 1991, Dr. Richman has been in practice at Hospital for Special Surgery (HSS) in the Department of Anesthesiology, Critical Care and Pain Management. Dr. Richman is also an assistant attending and clinical instructor within the Tri-Institutional Pain Management Fellowship in conjunction with New York-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center. For the past 15 years, Dr. Richman has consistently been rated among Castle Connolly Top Doctors as an expert in pain management in the New York City metropolitan area. Additionally, Dr. Richman specializes in orthopedic-related pain management with a specific interest in managing conditions related to the cervical, thoracic and lumbar spine. He is an expert in interventional treatments such as epidural steroid injections, diagnostic nerve blocks both under fluoroscopic and ultrasound guidance, radiofrequency denervation, sympathetic blockade and discography. Dr. Richman has extensive knowledge of managing advanced pain with implantable technology such as intrathecal pumps and spinal cord stimulators. His positive experience in prescribing medical cannabis for difficult neuropathic pain spurred his interest in exploring more extensive cannabidiol (CBD) applications for nerve pain.お知らせ • Sep 18Kannalife, Inc. Appoints Tage Honoré as the Chairman of the Company’s Board of AdvisorsKannalife, Inc. announced that it has appointed pharmaceutical and biotechnology industry veteran Dr. Tage Honoré as the Chairman of the Company’s Board of Advisors. Dr. Honoré is a world-renowned pharma and biotechnology executive, entrepreneur, and pioneer with expert knowledge in the fields of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy (HRT), learning disorders, osteoporosis, Parkinson’s disease, stroke, and schizophrenia. Among his many accomplishments is the discovery of the AMPA subtype of excitatory amino acid receptors, as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the excitatory pathways in the central nervous system (CNS). Additionally, Dr. Honoré has published more than 100 scientific papers, is the inventor on 23 patents, and has championed 40 drugs to progress from idea to clinical development, including Gabatril (tiagabine) and other novel compounds that entered the prescription drug market. The organizational models Dr. Honoré developed to obtain record pipeline productivity in several companies are key to his business achievements. He has held several positions, including: VP Drug Discovery at Novo Nordisk A/S; Senior Executive VP Nervous System Research at Novartis Pharma Inc; VP Discovery Research at Purdue Pharma LP; and President and CEO at Aestus Therapeutics Inc. Dr. Honoré has a master’s degree in pharmaceutical science and doctoral degrees in medicinal chemistry and neurobiology. He also has business training from Harvard Business School and European Management Centre.決済の安定と成長配当データの取得安定した配当: NPTXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: NPTXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Neuropathix 配当利回り対市場NPTX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (NPTX)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (NPTX) (最長3年)n/a注目すべき配当: NPTXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: NPTXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: NPTXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: NPTXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/22 23:35終値2023/10/19 00:00収益2022/03/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neuropathix, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 13Neuropathix, Inc. announced delayed 10-Q filingOn 08/12/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Neuropathix, Inc. announced delayed 10-Q filingOn 05/16/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Neuropathix, Inc. announced delayed annual 10-K filingOn 03/31/2022, Neuropathix, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 13Neuropathix, Inc. Appoints Daniel Richman to Board of AdvisorsNeuropathix, Inc. announced that it has appointed pain management expert Dr. Daniel Richman to the Company’s Board of Advisors. Dr. Richman is a world-renowned, board-certified attending anesthesiologist and pain management physician. Since 1991, Dr. Richman has been in practice at Hospital for Special Surgery (HSS) in the Department of Anesthesiology, Critical Care and Pain Management. Dr. Richman is also an assistant attending and clinical instructor within the Tri-Institutional Pain Management Fellowship in conjunction with New York-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center. For the past 15 years, Dr. Richman has consistently been rated among Castle Connolly Top Doctors as an expert in pain management in the New York City metropolitan area. Additionally, Dr. Richman specializes in orthopedic-related pain management with a specific interest in managing conditions related to the cervical, thoracic and lumbar spine. He is an expert in interventional treatments such as epidural steroid injections, diagnostic nerve blocks both under fluoroscopic and ultrasound guidance, radiofrequency denervation, sympathetic blockade and discography. Dr. Richman has extensive knowledge of managing advanced pain with implantable technology such as intrathecal pumps and spinal cord stimulators. His positive experience in prescribing medical cannabis for difficult neuropathic pain spurred his interest in exploring more extensive cannabidiol (CBD) applications for nerve pain.
お知らせ • Sep 18Kannalife, Inc. Appoints Tage Honoré as the Chairman of the Company’s Board of AdvisorsKannalife, Inc. announced that it has appointed pharmaceutical and biotechnology industry veteran Dr. Tage Honoré as the Chairman of the Company’s Board of Advisors. Dr. Honoré is a world-renowned pharma and biotechnology executive, entrepreneur, and pioneer with expert knowledge in the fields of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy (HRT), learning disorders, osteoporosis, Parkinson’s disease, stroke, and schizophrenia. Among his many accomplishments is the discovery of the AMPA subtype of excitatory amino acid receptors, as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the excitatory pathways in the central nervous system (CNS). Additionally, Dr. Honoré has published more than 100 scientific papers, is the inventor on 23 patents, and has championed 40 drugs to progress from idea to clinical development, including Gabatril (tiagabine) and other novel compounds that entered the prescription drug market. The organizational models Dr. Honoré developed to obtain record pipeline productivity in several companies are key to his business achievements. He has held several positions, including: VP Drug Discovery at Novo Nordisk A/S; Senior Executive VP Nervous System Research at Novartis Pharma Inc; VP Discovery Research at Purdue Pharma LP; and President and CEO at Aestus Therapeutics Inc. Dr. Honoré has a master’s degree in pharmaceutical science and doctoral degrees in medicinal chemistry and neurobiology. He also has business training from Harvard Business School and European Management Centre.